特洛恩疗法公司美股招股说明书(2025-11-17版)

PROSPECTUS SUPPLEMENT(to Prospectus dated September 30, 2025) Turn Therapeutics Inc.17,868,760 Shares of Common Stock This prospectus supplement supplements the prospectus dated September 30, 2025 (the “Prospectus”), which forms a part of ourregistration statement on FormS-1(File No.333-289972). This prospectus supplement is being filed to update and supplement the information in the Prospectus with the informationcontained in our quarterly report on Form10-Q for the quarterly period ended September 30, 2025,filed with the Securities andExchange Commission on November 13, 2025 (the “Quarterly Report”). Accordingly, we have attached the Quarterly Report to this The Prospectus relates to the registration of the resale of up to 17,868,760 shares of our common stock, par value $0.0001 pershare (the “common stock”), by the stockholders identified in the Prospectus. This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunctionwith the Prospectus, which is required to be delivered with this prospectus supplement. If there is any inconsistency between the Our shares of common stock are listed on the Nasdaq Global Market (“Nasdaq”) under the symbol “TTRX”. On November 14,2025, the closing price of our common stock, as reported on Nasdaq, was $4.00 per share. We are an “emerging growth company” under federal securities laws and are subject to reduced public company reportingrequirements. Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertaintiesdescribed under the heading “RiskFactors” beginning on page20 of the Prospectus, and under similar headings in anyamendment or supplements to the Prospectus, including this prospectus supplement. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved ofthese securities or passed upon the adequacy or accuracy of the Prospectus. Any representation to the contrary is a criminal The date of this prospectus supplement is November 17, 2025. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (the “Quarterly Report”) contains forward-looking statements concerning our business,operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations andfinancial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to beforward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,”“contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,”“positioned,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of or indicate future eventsand future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are ●our expectations with regard to the results of our clinical studies, preclinical studies and research and developmentprograms, including the timing and availability of data from such studies; ●the location, timing of commencement and data reporting of future nonclinical studies and clinical trials and research anddevelopment programs; ●our clinical and regulatory development plans; ●our expectations regarding the product profile, relative benefits and clinical utility of our product candidates; ●our expectations regarding the potential market size and size of the potential patient populations for our productcandidates and any future product candidates if approved for commercial use; ●our ability to acquire, discover, develop and advance our product candidates into, and successfully complete, clinicaltrials; ●our intentions and our ability to establish collaborations and/or partnerships; ●the timing or likelihood of regulatory filings and approvals for our product candidates; ●our commercialization, marketing and manufacturing capabilities and expectations; ●our intentions with respect to the commercialization of our product candidates; ●the pricing and reimbursement of our product candidates, if approved; ●the implementation of our business model and strategic plans for our business and product candidates, includingadditional indications which we may pursue or elect not to pursue; ●the scope of protection we are able to establish, maintain, protect and enforce for intellectual property rights covering ourproduct candidates, including the projected terms of patent protection; ●estimates of our expenses, future revenue, capital requirements, our needs for additional financing and our ability toobtain additional capital and the timing of the sufficiency of our capital resourc